Seagen (SGEN) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Seagen Reports Third Quarter 2022 Financial Results
October 27, 2022 4:02 PM EDT-Total Revenues of $510 Million in 3Q22, Including Net Product Sales of $428 Million-
-Submitted Supplemental Biologics License Application to FDA for PADCEV in Combination with KEYTRUDA as First-Line Treatment for Advanced Urothelial Cancer-
-Announced FDA Granted Priority Review for TUKYSA in Combination with Trastuzumab for Previously Treated HER2-Positive Metastatic Colorectal Cancer-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq: SGEN) reported financial results today for the third quarter ended September 30, 2022. The Company also highlighted PADCEV®... More
